ZAI LAB LTD0000006 (1ZLB) - Total Liabilities
Based on the latest financial reports, ZAI LAB LTD0000006 (1ZLB) has total liabilities worth €433.76 Million EUR (≈ $507.11 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 1ZLB long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
ZAI LAB LTD0000006 - Total Liabilities Trend (2021–2025)
This chart illustrates how ZAI LAB LTD0000006's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 1ZLB total asset value.
ZAI LAB LTD0000006 Competitors by Total Liabilities
The table below lists competitors of ZAI LAB LTD0000006 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jiangsu Changling Hydraulic Co. Ltd
SHG:605389
|
China | CN¥260.48 Million |
|
Monadelphous Group Ltd
F:8MP
|
Germany | €421.77 Million |
|
ALPEK S.A.B. de C.V
MX:ALPEKA
|
Mexico | MX$74.41 Billion |
|
African Rainbow Minerals Ltd
JSE:ARI
|
South Africa | ZAC14.20 Billion |
|
Australian United Investment Company Ltd
AU:AUI
|
Australia | AU$399.22 Million |
|
Sparebank 1 Nord-Norge
OL:NONG
|
Norway | Nkr124.99 Billion |
|
InfoVision Optoelectronics Kunshan Co Ltd
SHG:688055
|
China | CN¥2.50 Billion |
|
Klabin S.A
SA:KLBN3
|
Brazil | R$47.70 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down ZAI LAB LTD0000006's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 1ZLB net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.40 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.66 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.40 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ZAI LAB LTD0000006's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ZAI LAB LTD0000006 (2021–2025)
The table below shows the annual total liabilities of ZAI LAB LTD0000006 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €456.88 Million ≈ $534.15 Million |
+32.49% |
| 2024-12-31 | €344.86 Million ≈ $403.17 Million |
+43.58% |
| 2023-12-31 | €240.18 Million ≈ $280.79 Million |
+37.60% |
| 2022-12-31 | €174.54 Million ≈ $204.06 Million |
-24.11% |
| 2021-12-31 | €230.00 Million ≈ $268.89 Million |
-- |
About ZAI LAB LTD0000006
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for … Read more